IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Benjamin Edwards Inc.

Benjamin Edwards Inc. grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 661.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,880 shares of the company's stock after purchasing an additional 1,633 shares during the quarter. Benjamin Edwards Inc.'s holdings in IDEXX Laboratories were worth $950,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of IDXX. FSA Wealth Management LLC purchased a new position in IDEXX Laboratories in the 3rd quarter valued at $25,000. Ridgewood Investments LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at about $27,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after buying an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC lifted its stake in shares of IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock worth $34,000 after buying an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in IDEXX Laboratories during the third quarter worth about $37,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analysts Set New Price Targets

IDXX has been the subject of a number of recent research reports. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a report on Thursday, October 10th. JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a research report on Friday, October 11th. Piper Sandler reiterated a "neutral" rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, November 28th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $546.56.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now owns 905 shares of the company's stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.11% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Trading Up 1.9 %

Shares of NASDAQ IDXX traded up $8.20 during mid-day trading on Friday, reaching $435.69. 551,918 shares of the company's stock were exchanged, compared to its average volume of 649,999. The company's 50-day moving average is $444.47 and its 200-day moving average is $474.16. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The firm has a market capitalization of $35.68 billion, a price-to-earnings ratio of 42.01, a PEG ratio of 3.97 and a beta of 1.37. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. IDEXX Laboratories's revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.53 earnings per share. Analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.